9 results about "CD1D" patented technology

The present invention provides a liposome preparation containing a population of liposomes containing a CD1d ligand compound, wherein the average particle size of the population of liposomes is 90 to 110 nm and the polydispersity index of particle size distribution is 0.2 or less. and the polydispersity index of the particle size distribution is 0.2 or less. The present invention also provides the use of the liposome preparation in the prevention or treatment of graft-versus-host disease and organ transplant rejection.

This invention provides novel compositions and methods for effectively stimulating antiviral immunity. [Solution] A composition comprising (a) a vector comprising a plasmid encoding at least one viral antigen; and (b) a vector comprising a CD1d recognition antigen; and (c) at least one pharmaceutically acceptable carrier, wherein at least one of vectors (a) and (b) is an intact bacterial minicell or a dead bacterial cell.

The present disclosure is directed to compositions comprising fusion proteins of CD1d and anti-GD2 antibody that may be used as GD2-specific Bi-specific invariant natural killer T cell engagers (BiNTEs). Further provided herein are methods of using the fusion proteins or BiNTEs for the treatment of cancer.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

It can remain in the bloodstream for a long period, allowing for the maintenance of high blood concentrations of the active ingredient over extended periods. To provide a liposome formulation containing a CD1d ligand compound that can perform the necessary functions. [Solution] The present invention provides a liposome formulation comprising a group of liposomes containing a CD1d ligand compound, wherein the average particle size of the group of liposomes is 90 to 110 nm, and the polydispersity of the particle size distribution is 0.2 or less. The present invention also provides a method for producing the formulation.

The invention belongs to the technical field of chemistry and medicine, and relates to a natural killer T cell agonist containing a bifurcated or macrocyclic acyl chain structure and having immunoregulatory activity and an application of the natural killer T cell agonist. The agonist is a compound with a structure as shown in a formula (1) or a pharmaceutically acceptable salt thereof. According to the invention, a branched chain or a macrocyclic structure is introduced to an acyl chain of alpha GalCer, so that the binding force between glycolipid molecules and CD1d is enhanced. By adopting the design concept, the NKT cell agonist with better immunomodulatory activity is obtained, the synthesis method of the series of compounds is simple and efficient, and the screened novel alpha GalCer analogue has obviously improved immunostimulatory activity compared with the original alpha GalCer, can induce immunoreactions with different biases, and has good immunomodulatory activity. Potential candidate drugs are provided for immunotherapy and immune modulation.

Compositions and methods for treating diseases such as cancer or viral or bacterial infections are described. More specifically, provided compositions comprise an encapsulated CD1d restricted constant natural killer T cell antigen, a bacterial alpha-galactosylceramide.

The invention provides a nano vaccine targeting iNKT cells, a preparation method of the nano vaccine and application of the nano vaccine in preparation of anti-tumor preparations, and belongs to the technical field of biological medicines. A recombinant protein expression technology is adopted, cysteine is introduced to the C end of CD1d protein, sulfydryl of the cysteine is coupled with maleimide groups on the surfaces of ferroferric oxide nanoparticles, the CD1d protein is directionally coupled to the surfaces of the nanoparticles, then alpha GalCer lipid antigens are loaded, and the nano vaccine capable of directly activating iNKT cells is constructed. The nano vaccine for targeting the iNKT cells simulates dendritic cells in vivo to play an antigen presentation role, further specifically activates the iNKT cells, induces the iNKT cells to proliferate and release cytokines, shows a good immune activation effect in cell and animal experiments, can effectively relieve alphaGalCer-induced iNKT cell inability, and has a good immune activation effect. And an excellent anti-tumor effect is shown in various tumor models.

The invention belongs to the technical field of biological medicines, and discloses an immune checkpoint blocking therapy for targeted NKT cells. The platform comprises a hollow mesoporous MnO2 nano catalytic core, a glutamine metabolism regulator PRCG loading layer and surface CD1d-alpha-GalCer compound modification, and through high active oxygen in-situ removal, pH / H2O2 responsive drug release and NKT cell specific targeting, the metabolic activity and the anti-tumor function of the platform are synergistically recovered. The core bottleneck problem of metabolic dysfunction caused by high active oxygen level of NKT cells in a tumor microenvironment is successfully solved by constructing a multifunctional nano-platform integrating targeted recognition, in-situ catalysis and metabolic reprogramming, the oxidative stress in the cells is remarkably reduced, ATP generation and IFN-gamma secretion are improved, and the tumor microenvironment is improved. The tumor suppression effect and the immune memory are enhanced when the polypeptide is combined with a PD-1 antibody, and the polypeptide has good biological safety.